Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 306

1.

Effect of dutasteride on clinical progression of benign prostatic hyperplasia in asymptomatic men with enlarged prostate: a post hoc analysis of the REDUCE study.

Toren P, Margel D, Kulkarni G, Finelli A, Zlotta A, Fleshner N.

BMJ. 2013 Apr 15;346:f2109. doi: 10.1136/bmj.f2109.

2.

Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.

Roehrborn CG, Nickel JC, Andriole GL, Gagnier RP, Black L, Wilson TH, Rittmaster RS.

Urology. 2011 Sep;78(3):641-6. doi: 10.1016/j.urology.2011.03.063. Epub 2011 Jul 20.

PMID:
21764428
4.
5.

Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia.

Roehrborn CG, Marks LS, Fenter T, Freedman S, Tuttle J, Gittleman M, Morrill B, Wolford ET.

Urology. 2004 Apr;63(4):709-15.

PMID:
15072886
6.

Effect of dutasteride on the risk of prostate cancer.

Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, Rittmaster RS; REDUCE Study Group.

N Engl J Med. 2010 Apr 1;362(13):1192-202. doi: 10.1056/NEJMoa0908127.

7.

The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.

Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Nandy I, Morrill BB, Gagnier RP, Montorsi F; CombAT Study Group.

Eur Urol. 2010 Jan;57(1):123-31. doi: 10.1016/j.eururo.2009.09.035. Epub 2009 Sep 19. Erratum in: Eur Urol. 2010 Nov;58(5):801.

PMID:
19825505
8.

Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia.

Debruyne F, Barkin J, van Erps P, Reis M, Tammela TL, Roehrborn C; ARIA3001, ARIA3002 and ARIB3003 Study Investigators.

Eur Urol. 2004 Oct;46(4):488-94; discussion 495.

PMID:
15363566
9.

Comparison of the response to treatment between Asian and Caucasian men with benign prostatic hyperplasia: long-term results from the combination of dutasteride and tamsulosin study.

Chung BH, Lee SH, Roehrborn CG, Siami PF, Major-Walker K, Wilson TH, Montorsi F; CombAT Study Group.

Int J Urol. 2012 Nov;19(11):1031-5. doi: 10.1111/j.1442-2042.2012.03091.x. Epub 2012 Jul 9.

10.

Re: effect of dutasteride on clinical progression of benign prostatic hyperplasia in asymptomatic men with enlarged prostate: a post hoc analysis of the REDUCE study.

Kaplan SA.

J Urol. 2014 Feb;191(2):424. doi: 10.1016/j.juro.2013.10.089. Epub 2013 Oct 25. No abstract available.

PMID:
24411886
11.

The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.

Roehrborn CG, Siami P, Barkin J, Damião R, Becher E, Miñana B, Mirone V, Castro R, Wilson T, Montorsi F; CombAT Study Group.

Eur Urol. 2009 Feb;55(2):461-71. doi: 10.1016/j.eururo.2008.10.037. Epub 2008 Nov 6.

PMID:
19013011
12.

Dutasteride reduces prostate size and prostate specific antigen in older hypogonadal men with benign prostatic hyperplasia undergoing testosterone replacement therapy.

Page ST, Hirano L, Gilchriest J, Dighe M, Amory JK, Marck BT, Matsumoto AM.

J Urol. 2011 Jul;186(1):191-7. doi: 10.1016/j.juro.2011.03.026. Epub 2011 May 14.

13.

Dutasteride treatment over 2 years delays prostate-specific antigen progression in patients with biochemical failure after radical therapy for prostate cancer: results from the randomised, placebo-controlled Avodart After Radical Therapy for Prostate Cancer Study (ARTS).

Schröder F, Bangma C, Angulo JC, Alcaraz A, Colombel M, McNicholas T, Tammela TL, Nandy I, Castro R.

Eur Urol. 2013 May;63(5):779-87. doi: 10.1016/j.eururo.2012.11.006. Epub 2012 Nov 12.

PMID:
23176897
14.

Efficacy and safety of dutasteride in Japanese men with benign prostatic hyperplasia.

Tsukamoto T, Endo Y, Narita M.

Int J Urol. 2009 Sep;16(9):745-50. doi: 10.1111/j.1442-2042.2009.02357.x. Epub 2009 Aug 5.

15.

Dutasteride improves objective and subjective disease measures in men with benign prostatic hyperplasia and modest or severe prostate enlargement.

Gittelman M, Ramsdell J, Young J, McNicholas T.

J Urol. 2006 Sep;176(3):1045-50; discussion 1050.

PMID:
16890688
16.

Dutasteride, who is it more effective for? Second to fourth digit ratio and the relationship with prostate volume reduction by dutasteride treatment.

Kim TB, Oh JK, Kim KH, Jung H, Yoon SJ, Lee MS, Kim SW.

BJU Int. 2012 Dec;110(11 Pt C):E857-63. doi: 10.1111/j.1464-410X.2012.11343.x. Epub 2012 Jul 3.

17.

Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia.

Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G; ARIA3001 ARIA3002 and ARIA3003 Study Investigators.

Urology. 2002 Sep;60(3):434-41.

PMID:
12350480
18.

Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor.

O'Leary MP, Roehrborn C, Andriole G, Nickel C, Boyle P, Höfner K.

BJU Int. 2003 Aug;92(3):262-6.

19.

Benign prostatic hyperplasia progression and its impact on treatment.

Djavan B, Waldert M, Ghawidel C, Marberger M.

Curr Opin Urol. 2004 Jan;14(1):45-50. Review.

PMID:
15091050
20.

Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia.

Andriole GL, Roehrborn C, Schulman C, Slawin KM, Somerville M, Rittmaster RS.

Urology. 2004 Sep;64(3):537-41; discussion 542-3.

PMID:
15351586
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk